Heart Lung Circ. 2021 May 12:S1443-9506(21)00499-6. doi: 10.1016/j.hlc.2021.04.018. Online ahead of print.
Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.
PMID:34049806 | DOI:10.1016/j.hlc.2021.04.018